MHC binding peptides and their uses

Abstract

The present invention is concerned with MHC binding peptides derived from the avian influenza virus H5N1 and in particular MHC class I restricted binding peptides from the Haemagglutinin 5 (H5) protein from this virus and their uses.

Description

Claims

1. An isolated peptide selected from the group consisting of:

2. A DNA or RNA sequence encoding one or more of the peptides of claim 1.

3. A vector comprising a DNA or RNA sequence of claim 2.

4. An MHC-peptide complex comprising one or more of the peptides of claim 1.

5. An oligomeric MHC-peptide complex comprising one or more of the peptides of claim 1.

6. An antibody specific to one or more of the peptides of claim 1 or an MHC-peptide complex comprising one or more of the peptides of claim 1.

7. A cytolytic T cell line or clone specific to one or more of the peptides of claim 1.

8. A dendritic cell primed with one or more of the peptide of claim 1.

9. A pharmaceutical composition comprising one or more selected from the group consisting of one or more of the peptides of claim 1, a DNA or RNA sequence of claim 2, a vector of claim 3, an MHC-peptide complex of claim 4, an oligomeric MHC-peptide complex of claim 5, an antibody of claim 6, a cytolytic T cell line or clone of claim 7, and a dendritic cell of claim 8.

10. A diagnostic composition comprising a label and one or more selected from the group consisting of one or more of the peptides of claim 1, a DNA or RNA sequence of claim 2, a vector of claim 3, an MHC-peptide complex of claim 4, an oligomeric MHC-peptide complex of claim 5, an antibody of claim 6, a cytolytic T cell line or clone of claim 7, and a dendritic cell of claim 8.